Replies to post #20762 on Biotech Values

[Praveen]

ELAN/TEVA

Hi ioio,

Thanks, I will stick to my ELAN then. I read the info on other boards too, but I guess they are quoting from Bloomberg.

Copaxone has sales of 936 Million$ last year and will be more this year. But in 2006, when T hits the market and also MNTA is planning to file a biogeneric for copaxone(copaxone's patents have already expired), Also most of TEVA's revenues are from copaxone if I am right...

Short TEVA?

:-)Praveen